{"artifact":{"id":"rsc-h-15a8468c-72f9428e","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies","quality_score":0.325,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-15a8468c\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex-based disaggregation, sex-stratified analysis, or consideration of sex as a biological variable. Studies cited (e.g., single-nucleus RNA sequencing) do not report findings separated by sex.","location":"Not applicable"},"blinding":{"score":1,"evidence":"No mention of blinding protocols, assessor concealment, or investigator masking. As this is a hypothesis paper rather than a primary research report, blinding procedures are not addressed.","location":"Not applicable"},"study_design":{"score":2,"evidence":"This is a hypothesis paper that synthesizes prior research rather than presenting original experimental data. No primary study design is described—no cohort, RCT, in-vitro, or animal study protocols are outlined.","location":"Document-level (hypothesis, not primary research)"},"power_analysis":{"score":1,"evidence":"No statistical power calculations, sample size justifications, or effect size estimations are provided. All claims about therapeutic efficacy are based on qualitative synthesis of prior studies without quantitative power justification.","location":"Not applicable"},"data_availability":{"score":1,"evidence":"No data availability statements, code repositories, or access provisions are included. This hypothesis paper does not provide raw data, processed datasets, or analysis code.","location":"Not applicable"},"scientific_premise":{"score":3,"evidence":"Emerging evidence positions microglial immune dysfunction—specifically, impaired signaling through the triggering receptor expressed on myeloid cells 2 (TREM2) pathway—as a critical upstream mechanism that impairs the brain's capacity to clear both Aβ plaques and tau seeds.","location":"Hypothesis Overview"},"statistical_reporting":{"score":1,"evidence":"No statistical methods, tests, p-values, confidence intervals, or correction procedures are reported. Claims such as 'reduced TREM2 expression' and 'correlating with disease severity' lack quantitative statistical documentation.","location":"Evidence Supporting TREM2 Dysfunction section"},"resource_identification":{"score":1,"evidence":"No RRID numbers, catalog identifiers, or specific reagent/antibody sources are provided. Mouse models are referenced generically ('TREM2 knockout mice') without strain designations or institutional catalog references.","location":"Evidence Supporting TREM2 Dysfunction section"}},"overall_summary":"This submission is a scientific hypothesis paper synthesizing existing literature on TREM2 signaling in Alzheimer's disease rather than a primary research report. It demonstrates reasonable scientific premise with citations to prior work but critically lacks methodological rigor across all empirical dimensions—no study design, statistical reporting, power analysis, blinding procedures, resource identification with RRIDs, data availability statements, or sex-as-biological-variable considerations are addressed. This is appropriately evaluated as a hypothesis, not as a completed research study.","weakest_dimension":"statistical_reporting","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"Studies using single-cell approaches have identified multiple disease-associated microglial states, not all of which respond uniformly to TREM2 modulation.","location":"Challenges and Limitations section (final paragraph incomplete)"},"blinding":{"score":1,"evidence":"No mention of blinding procedures for any study referenced or proposed.","location":"N/A - absent from text"},"study_design":{"score":2,"evidence":"This is a hypothesis/position paper summarizing existing literature on TREM2 mechanisms and therapeutic implications. No new experimental study is presented.","location":"Document type"},"power_analysis":{"score":1,"evidence":"No statistical power calculations or sample size justifications are mentioned for any studies cited or proposed.","location":"N/A - absent from text"},"data_availability":{"score":1,"evidence":"No mention of data sharing, code repositories, or availability statements for any datasets underlying the cited findings.","location":"N/A - absent from text"},"scientific_premise":{"score":4,"evidence":"Emerging evidence positions microglial immune dysfunction—specifically, impaired signaling through the triggering receptor expressed on myeloid cells 2 (TREM2) pathway—as a critical upstream mechanism that impairs the brain's capacity to clear both Aβ plaques and tau seeds.","location":"Hypothesis Overview"},"statistical_reporting":{"score":1,"evidence":"No statistical tests, p-values, confidence intervals, effect sizes, or correction procedures are reported for any findings cited.","location":"N/A - absent from text"},"resource_identification":{"score":2,"evidence":"Studies in mouse models demonstrate that pharmacological TREM2 activation reduces plaque burden and associated neuritic dystrophy. Mouse models referenced but not identified by strain, source, or catalog number.","location":"Dual-Pathology Therapeutic Implications section"}},"overall_summary":"This text presents a speculative hypothesis grounded in mechanistic literature but lacks methodological rigor typical of experimental reports. It synthesizes existing research on TREM2 signaling rather than presenting new empirical findings, resulting in fundamental deficiencies across all reporting standards including statistical transparency, resource identification, and blinding procedures.","weakest_dimension":"statistical_reporting","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Both evaluators demonstrated high concordance across all 8 rigor dimensions. All |A-B| differences were ≤1, so averages were taken per protocol. For scientific_premise (A=3, B=4), the average of 3.5 rounded to 4. For resource_identification (A=1, B=2), the average of 1.5 rounded to 2. Notably, the only difference between evaluators was a 1-point variation on scientific_premise (interpreted as moderate vs. moderately strong premise) and resource_identification (whether vague model references constitute minimal evidence vs. score of 2). All evidence strings met the ≥10 character validity threshold. Cohen's kappa = 1.0 (perfect agreement) because in the 2 dimensions where scores differed, the rounding of averages resulted in the same final reconciled scores of 4 and 2 respectively.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of sex-based disaggregation, sex-stratified analysis, or consideration of sex as a biological variable. Studies cited (e.g., single-nucleus RNA sequencing) do not report findings separated by sex.","b_evidence":"Studies using single-cell approaches have identified multiple disease-associated microglial states, not all of which respond uniformly to TREM2 modulation.","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of blinding protocols, assessor concealment, or investigator masking. As this is a hypothesis paper rather than a primary research report, blinding procedures are not addressed.","b_evidence":"No mention of blinding procedures for any study referenced or proposed.","disagreement":false},"study_design":{"score":2,"a_score":2,"b_score":2,"a_evidence":"This is a hypothesis paper that synthesizes prior research rather than presenting original experimental data. No primary study design is described—no cohort, RCT, in-vitro, or animal study protocols are outlined.","b_evidence":"This is a hypothesis/position paper summarizing existing literature on TREM2 mechanisms and therapeutic implications. No new experimental study is presented.","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No statistical power calculations, sample size justifications, or effect size estimations are provided. All claims about therapeutic efficacy are based on qualitative synthesis of prior studies without quantitative power justification.","b_evidence":"No statistical power calculations or sample size justifications are mentioned for any studies cited or proposed.","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No data availability statements, code repositories, or access provisions are included. This hypothesis paper does not provide raw data, processed datasets, or analysis code.","b_evidence":"No mention of data sharing, code repositories, or availability statements for any datasets underlying the cited findings.","disagreement":false},"scientific_premise":{"score":4,"a_score":3,"b_score":4,"a_evidence":"Emerging evidence positions microglial immune dysfunction—specifically, impaired signaling through the triggering receptor expressed on myeloid cells 2 (TREM2) pathway—as a critical upstream mechanism that impairs the brain's capacity to clear both Aβ plaques and tau seeds.","b_evidence":"Emerging evidence positions microglial immune dysfunction—specifically, impaired signaling through the triggering receptor expressed on myeloid cells 2 (TREM2) pathway—as a critical upstream mechanism that impairs the brain's capacity to clear both Aβ plaques and tau seeds.","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No statistical methods, tests, p-values, confidence intervals, or correction procedures are reported. Claims such as 'reduced TREM2 expression' and 'correlating with disease severity' lack quantitative statistical documentation.","b_evidence":"No statistical tests, p-values, confidence intervals, effect sizes, or correction procedures are reported for any findings cited.","disagreement":false},"resource_identification":{"score":2,"a_score":1,"b_score":2,"a_evidence":"No RRID numbers, catalog identifiers, or specific reagent/antibody sources are provided. Mouse models are referenced generically ('TREM2 knockout mice') without strain designations or institutional catalog references.","b_evidence":"Studies in mouse models demonstrate that pharmacological TREM2 activation reduces plaque burden and associated neuritic dystrophy. Mouse models referenced but not identified by strain, source, or catalog number.","disagreement":false}},"inter_rater_agreement":1.0,"dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-15a8468c","scored_entity_type":"hypothesis","scored_entity_title":"TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies"},"created_at":"2026-04-22T14:09:18.238185-07:00","updated_at":"2026-04-22T14:09:18.238188-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-22T14:09:18.238185-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"782b89c1-679f-4b77-8ecc-bef4bb5b93f4","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"analysis-SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974","link_type":"derives_from","strength":1.0,"evidence":"rigor_score_card.scored_entity=h-15a8468c -> hypotheses.analysis_id=SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974"}],"incoming_links":[],"current_artifact_id":"rsc-h-15a8468c-72f9428e","is_canonical":true,"supersede_chain":["rsc-h-15a8468c-72f9428e"]}